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Vitiligo is one of the most striking of
all human disease phenotypes, and is
perhaps the most common pigmentary
disorder. The patchy loss of skin pig-
mentation and the marked contrast
between involved and uninvolved
skin particularly impacts persons of
color, with consequent stigmatization
that has long been recognized to result
in significant social inequality and
morbidity in affected individuals (Brito,
1885). Because of its visually evident
cutaneous manifestations, vitiligo has
been known for thousands of years.
However, only relatively recently has
there been real progress in understand-
ing its pathobiological basis, which,
it is hoped, may facilitate progress in
vitiligo treatment and ultimately even
prevention. Surprisingly, in several
instances key discoveries seem to have
been overlooked or discounted, only
to be rediscovered and republished by
others a decade or more later.
Clinical studies of vitiligo remained
relatively primitive until the late 1950s,
when Lerner (1959) reported the first
systematic investigation of a large
patient series, suggesting the descrip-
tive classification that is still essentially
in use today. In the treatment arena,
repigmentation of vitiligo by topical
or oral use of Ammi majus or Psoralia
corylifolia plant extracts or seeds,
particularly when combined with sun
exposure, was known in ancient Egypt,
India, China, and Japan, but was not
part of Western medical practice (Lind-
say, 1932). It was not until after the
Second World War that specific treat-
ment of vitiligo was pioneered by
Menon (1945) in India using UV light
and by El Mofty (1948) in Egypt using
the crystallized active components of
Ammi majus, mainly 8-methoxypsora-
len, both alone and in combination
with exposure to sunlight or UV light.
Despite extensive (and sometimes
fairly wild) speculation, the patho-
biology of vitiligo remained completely
unknown until the next milestone, the
elegant demonstration by Hu et al.
(1959) that the affected skin of patients
with generalized vitiligo, the most
common form of the disorder, largely
lacked melanocytes, whereas melano-
cytes were present in both uninvolved
and repigmented skin of the same
patients. These same authors also
noted the transfer of pigment from
melanocytes to epithelial cells follow-
ing UV irradiation, which was probably
the first recognition and description
of what later came to be called
the ‘‘epidermal-melanin unit’’. These
observations led them to conclude
that successful treatment of vitiligo
therefore must depend on either
proliferation of residual functional
melanocytes within vitiligo lesions or
inward migration and proliferation of
melanocytes from surrounding normal
skin, as well as an intact ability of
epithelial cells to receive pigment from
active melanocytes.
Although the specific pathogenic
mechanism underlying melanocyte dis-
appearance or destruction in vitiligo
remained obscure, the earliest clue to
an autoimmune origin, and perhaps the
earliest milestone in vitiligo, was the
report by Addison (1855) of a patient
with idiopathic adrenal insufficiency,
generalized vitiligo, and pernicious
anemia. The frequent concomitant
occurrence of multiple autoimmune
diseases, including generalized vitiligo,
was subsequently documented in many
reports, particularly in that of Schmidt
(1926), and was later codified by
Neufeld and Blizzard (1980). In an
1872 lecture to the Silesian Society for
National Culture, Ko¨bner, an eccentric
German dermatologist and mycologist,
described the ‘‘isomorphe Reizeffekt’’
(Ko¨bner, 1876), now known as the
‘‘Koebner phenomenon’’, the appear-
ance of new, localized lesions at
sites of skin injury in psoriasis, which
was quickly extended to vitiligo and
many other skin disorders that have a
major autoimmune or autoinflamma-
tory component (Hebra and Kaposi,
1874). Langhof et al. (1965) reported
autoantibodies to melanocyte compo-
nents, and Gross et al. (1987) identified
perilesional infiltrates of cytotoxic
T-lymphocytes in patients with vitiligo.
There were also numerous case reports
of vitiligo developing in patients
with malignant melanoma, particularly
in those treated by immunotherapy
(Burdick and Hawk, 1964). Despite all
of these indicators, there was surpris-
ingly enduring resistance to the accep-
tance of generalized vitiligo as an
autoimmune disease.
The role of genetic factors in vitiligo
was also considered early because of
the frequent clustering of cases among
close relatives (Stuttgen, 1950; Teindel,
1950), and eventual genetic epidemio-
logical studies by Das et al. (1985)
supported multifactorial, polygenic
inheritance, which currently is termed
‘‘complex disease’’. Typical of the
1960s and 1970s, ABO, haptoglobin,
erythrocyte enzymes, and various
serum proteins were tested as genetic
markers for vitiligo, with negative
results. Beginning in the 1970s, a
plethora of analyses of HLA in vitiligo
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were reported, with equivocal and
conflicting findings. Subsequently,
genetic association of vitiligo with many
other candidate genes was studied and
reported, though only PTPN22 and
perhaps CTLA4, both of which encode
immune regulators, are given high
credence today. The modern era of
genetic studies of generalized vitiligo
began indirectly, with the identification
of SLEV1 on chromosome 17p13, a
linkage signal in systemic lupus erythe-
matosus families that also included
at least one relative with vitiligo (Nath
et al., 2001), underscoring a causal
genetic relationship between these two
diseases. SLEV1 was later identified as
NLRP1 (NALP1), a key regulator of the
innate immune system (Jin et al., 2007).
The most important recent vitiligo
developments were two large-scale
genomewide association studies of
generalized vitiligo, one in Caucasians
(Jin et al., 2010) and the other in
Chinese (Quan et al., 2010), which
together identified and confirmed at
least 16 different loci that contribute
to generalized vitiligo susceptibility. All
but one of these genes encode proteins
involved in regulation of the immune
system and/or have been genetically
associated with susceptibility to other
autoimmune diseases. The sole excep-
tion is TYR, encoding tyrosinase, the
key enzyme of melanin biosynthesis
and the principal vitiligo autoimmune
antigen. In Caucasians, a common TYR
missense variant, R402Q, confers both
relative protection from generalized
vitiligo and relative susceptibility to
malignant melanoma, by modulating
the presentation of the TYR peptide by
HLA-A2*01, thereby modulating recog-
nition of melanocytes by the immune
system. These genes together account
for a relatively small fraction of the
genetic risk of generalized vitiligo,
indicating that many additional viti-
ligo susceptibility genes undoubtedly
remain to be discovered.
The results of the genetic studies
thus far show that generalized vitiligo is
a typical polygenic, multifactorial dis-
order, involving numerous different
susceptibility genes, and that the great
majority of these genes encode proteins
that regulate or mediate recognition or
destruction of melanocytes by the
immune system. Coupled with the
previous epidemiological and immu-
nological evidence, there is no longer
any doubt that generalized vitiligo is a
complex autoimmune disease, some
genes determining general suscepti-
bility to autoimmunity, and others
determining specific autoimmunity to
melanocytes. These findings begin to
highlight biological pathways that may
mediate the response of genetically
susceptible individuals to as-yet un-
known environmental triggers of disease
onset and their response to factors that
mediate or modify its clinical course, as
well as their response to treatment.
Furthermore, recent evidence sug-
gests that immune phenomena may
also contribute to the pathogenesis of
‘‘segmental vitiligo’’, a less common
form of the disorder, in which melano-
cyte loss remains quite localized,
often on the face, mostly occurring in
children and usually not associated
with other autoimmune diseases. Van
Geel et al. (2010) described a lympho-
cytic infiltrate of interferon-g-produ-
cing CD8þ and some CD4þ T cells
at the lesional margin in early segmen-
tal vitiligo, similar to those observed
in generalized vitiligo. Although occa-
sionally segmental vitiligo and general-
ized vitiligo occur in the same families,
it is uncertain whether this represents
more than mere coincidence; thus, the
true pathobiological relationship be-
tween generalized vitiligo and segmen-
tal vitiligo remains to be elucidated.
This deeper understanding of vitiligo
pathogenesis allows us to anticipate
future milestones. Of course, it is
hoped that new insights into disease
pathogenesis and pathways will pro-
vide clues to new drugs or other thera-
peutic approaches. However, even in
the absence of new treatment modal-
ities, such deeper understanding also
dictates a reconsideration of the current
approaches to vitiligo treatment. Viti-
ligo is a chronic autoimmune disease.
Melanocyte destruction remains on-
going even during attempts at treat-
ment, possibly accounting, in part,
for the uneven therapeutic response
and long-term clinical course. It may
therefore prove optimal to investigate
combined approaches to treatment,
including both immunosuppressive
and immunoregulatory approaches
that aim to reduce melanocyte destruc-
tion, while also including regenerative
approaches that aim to promote mela-
nocyte repopulation of depigmented
regions. Likewise, an improved under-
standing of what vitiligo is also helps
clarify what it is not. The first Prime
Minister of India, Jawaharlal Nehru,
reportedly ranked vitiligo, leprosy, and
tuberculosis as the three most impor-
tant medical problems in India (later
citations state malaria rather than
tuberculosis). Particularly in India, viti-
ligo and leprosy have long been con-
fused, with a consequent inappropriate
stigmatization of vitiligo. In an effort to
combat this erroneous stigmatization,
on 27 December 2010, the Indian State
of Tamil Nadu issued a Government
Order that the terms ‘‘ven kushtam’’
and ‘‘ven kuttam’’, both meaning
‘‘white leprosy’’ and often used as
equivalent to ‘‘vitiligo’’, should be
abandoned. Truly, a milestone for
Indian vitiligo patients.
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